Intestinal inflammation and pain management.

Lilian Basso, Arnaud Bourreille, Gilles Dietrich

Journal: Current opinion in pharmacology 2016;25():50-5

PMID: 26629597

Full Text on Elsevier Science View on PubMed

Abstract

Intestinal inflammation results in the production of inflammatory pain-inducing mediators that may directly activate colon sensory neurons. Endogenous opioids produced by mucosal effector CD4(+) T lymphocytes identified as colitogenic may paradoxically counterbalance the local pro-algesic effect of inflammatory mediators by acting on opioid receptors expressed on sensory nerve endings. The review will focus on the endogenous immune-mediated regulation of visceral inflammatory pain, current pain treatments in inflammatory bowel diseases and prospectives on new opioid therapeutic opportunities to alleviate pain but avoiding common centrally-mediated side effects.

Address: INSERM, U1043, Toulouse F-31300, France; CNRS, U5282, Toulouse F-31300, France; Université de Toulouse, UPS, Toulouse F-31300, France.; INSERM, U913, Nantes F-44093, France; Université de Nantes, Institut des Maladies de l'Appareil Digestif, Nantes F-44093, France.; INSERM, U1043, Toulouse F-31300, France; CNRS, U5282, Toulouse F-31300, France; Université de Toulouse, UPS, Toulouse F-31300, France. Electronic address: [email protected].

DOI: 10.1016/j.coph.2015.11.004

Link outs

Free resources

Medical:

https://medlineplus.gov/nondrugpainmanagement.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-CD4-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Analgesics, Opioid, Humans, Inflammatory Bowel Diseases, Models, Immunological, Opioid Peptides, Pain Management, T-Lymphocytes, Visceral Pain